Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 10 November 1995:
Vol. 270. no. 5238, p. 910
DOI: 10.1126/science.270.5238.910
Prev | Table of Contents | Next

News & Comment

Eliot Marshall

A controversial clinical trial to determine whether the drug tamoxifen can protect healthy women against breast cancer has run into a new obstacle. The National Heart, Lung, and Blood Institute, which was providing some funding, is reducing its commitment because it believes that the data will not shed light on tamoxifen's cardiovascular effects, as previously hoped.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)